Aprepitant Capsules 125 mg Lidocaine and Prilocaine 2.5%/2.5% Cream
March 9, 2023 -- Sandoz Inc. (“Sandoz”), in cooperation with the U.S. Consumer Product Safety Commission (“CPSC”), is voluntarily implementing a CPSC-approved recall of two lot numbers of Aprepitant Capsules 125 mg and nine lot numbers of Lidocaine and Prilocaine 2.5%/2.5% Cream. The packaging of these lot numbers is not child-resistant as required by the Poison Prevention Packaging Act, posing a risk of harm if children ingest the drugs or put the cream on their skin. These products are intended for institutional use only and are marked accordingly. However, a relatively small number of units were distributed by wholesalers into the retail market.
Sandoz is offering consumers free child-resistant, resealable pouches in which to store the affected medication already in their possession.
This action is not a result of any quality or safety concerns with the medications for their intended use, so consumers should continue using the medication as directed by their physicians. However, due to the risk of harm to children, consumers should immediately secure the medication out of the sight and reach of children.
Aprepitant Capsules 125 mg
0781-2323-06 Blister Pack
Lidocaine and Prilocaine 2.5%/2.5% Cream
ACTION BY PATIENT:
Please order a free child-resistant, resealable pouch in which to store your medication by calling 866-300-2207. Representatives are available Monday – Friday, 8:00 am – 5:00 pm ET. You will be asked to provide your name, address, and number of pouches needed. The pouches will be sent to you directly via overnight mail delivery.
Click here to watch a videowith some easy instructions on how to use your child-resistant, re-sealable pouch.
The action is being conducted with the knowledge of the U.S. Food and Drug Administration.
Please report any adverse reactions or product related questions by calling Sandoz at (800) 525-8747. Customer service agents are available Monday – Friday from 8:30 am to 5:00 pm ET. Adverse events can also be reported to FDA online at www.fda.gov/medwatch/report.htm.
Additional medical information may be requested from the Sandoz Customer Interaction Center by calling (800) 525-8747.
We appreciate your immediate attention and cooperation, and sincerely regret this situation.
Company Contact: Leslie Pott 201-354-0279
Sandoz, Inc. Issues Nationwide Recall of One Lot of Enoxaparin Sodium Injection, USP 40mg/0.4 mL Due to Temperature Excursion during Shipping
FOR IMMEDIATE RELEASE – December 1, 2021 – Princeton, NJ, Sandoz Inc. (“Sandoz”) is initiating a recall of one lot (SAB06761A, Exp 04/2023) of Enoxaparin Sodium Injection, USP 40 mg/0.4 mL Single-Dose Syringes to the consumer level. A portion of lot SAB06761A experienced a temperature excursion during shipment. Enoxaparin Sodium for Injection Lot SAB06761A was shipped to customers in the months of September and October 2021.
The exposure to higher temperatures may have significantly impacted the recalled product’s (lot SAB06761A) effectiveness and thus there may be reasonable probability of risk for patients with health conditions that the product is intended to treat. Such patients could be at risk for blood clots blocking blood vessels, an artery, or traveling to other tissues or organs causing pain, swelling, stroke, clots to the lung or death as a result of the underlying condition. To date, Sandoz has not received any reports of adverse events or injuries related to this recall.
The product is used for prevention of deep vein thrombosis (DVT) a condition that occurs when a blood clot forms in a deep vein, usually in the legs that can occur after surgeries or in patients with restricted mobility during illness; or prevention of complications associated with heart attacks. The product is packaged in cartons containing ten 0.4 mL syringes, NDC 0781-3246-64. Enoxaparin Sodium Injection was distributed Nationwide in the USA to wholesalers and retailers.
Please note: this recall is specific to only one batch (SAB06761A) of Enoxaparin Sodium Injection, USP 40 mg/0.4 mL and does not apply to any other strengths of Sandoz Enoxaparin Sodium Injection, USP or to other lots of the 40 mg/0.4 mL SKU. Any product returned that is not associated with this recall will be destroyed and no credit issued.
Consumers who have Enoxaparin Sodium Injection, USP 40 mg/0.4 mL (NDC 00781-3246-64 and Lot number SAB06761A) which is being recalled, should stop taking the recalled product, immediately consult with their physician to attain another prescription, and return the product where originally purchased. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.Sandoz has already notified its wholesalers and retailers by mail and is arranging for return of all recalled product.
Pharmacists should contact Sedgwick directly by phone at 844-265-7389 or by email at [email protected] to request a recall packet. Representatives are available Monday – Friday, 8:00 am – 5:00 pm ET.
Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
Company Contact: Leslie Pott 201-354-0279
*Enoxaparin sodium injection is a product of Sandoz, Inc.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potentially,” “can,” “will,” “may,” “could,” “initiating,” or similar terms, or by express or implied discussions regarding the potential outcome of the nationwide recall of Enoxaparin Sodium Injection 40MG Lot #SAB06761A, or regarding potential future revenues from such product. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee as to the outcome of the nationwide recall of Enoxaparin Sodium Injection 40MG Lot #SAB06761A. In particular, our expectations regarding such product could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such product; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical need. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2020 sales of USD 9.6 billion.
Sandoz Inc. Issues Voluntary Recall of Ranitidine Hydrochloride Capsules 150mg and 300mg Due to an Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA), in the Product
Sandoz Inc.is voluntarily recalling all quantities and lots within expiry of Ranitidine Hydrochloride Capsules in the US to the consumer level because of confirmed contamination with N-Nitrosodimethylamine (NDMA) above levels established by the FDA in batches of Sandoz Ranitidine Hydrochloride Capsules. To date, Sandoz has not received any reports of adverse events related to use of the product as part of this recall.
Pharmacists are being requested to contact Stericycle directly 1-888-667-1497 Monday – Friday 8:00am – 5:00pm EST to request a recall packet.
Patients are asked to continue taking their medication and speak to their physician on alternative healthcare treatment options. Per U.S. Food and Drug Administration guidance, consumers are asked to continue taking their medication until they speak to their physician or pharmacist on alternate healthcare treatment options. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product. Consumers with questions regarding this recall can contact Sandoz at 1-800-525-8747 option # between 8:30am – 5:00pm Monday – Friday EST or www.us.sandoz.com for more information.
Risk Statement: NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.
Ranitidine Hydrochloride Capsules is an oral product, indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion and acid output is desirable. The affected Ranitidine Hydrochloride Capsule can be identified by NDC numbers stated on the product label.
Sandoz will be notifying its distributors and customers via overnight mail and via the Sandoz web site, and will arrange for returnof all recalled products. Wholesalers (direct customers) will be asked to immediately stop distribution and return any stock to Sandoz, and contact the retail pharmacies in their group to do the same. Pharmacies will be asked to immediately stop dispensing Sandoz Ranitidine Hydrochloride Capsules and return remaining stock to Sandoz by contacting Stericycle to request a recall packet. Consumers are asked to continue taking their medication and speak to their physician or pharmacist on alternate healthcare treatment options.
Consumers with questions regarding this recall can contactSandoz at 1-800-525-8747 option # between 8:30am – 5:00pm Monday – Friday EST or www.us.sandoz.com for more information. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration
Important Correction of Drug Information
Notice to Healthcare Professionals Regarding Sandoz's Bivalirudin for Injection, 250mg/vial
Sandoz recall of select blister packages of products in the U.S. due to packaging requirements for child resistance. Corrective action on packaging required.
Sandoz Inc has implemented a voluntary recall and notice of corrective action after discovering certain blister card packages distributed in the U.S. do not meet U.S. child-resistant packaging requirements, posing a risk of harm if the tablets are swallowed by children
Products dispensed in bottles are NOT impacted by this recall
There are no quality or safety issues with the medicines for their intended use
Patients should immediately secure impacted blister card packages and their contents to keep out of the sight and reach of children
Patients should continue to use the medicine as prescribed and call 1-888-NOW NOVA (1-888-669-6682) for important information on corrective actions
At Sandoz, we take our responsibility for consumer safety very seriously. The U.S. Consumer Product Safety Commission (CPSC) and Food and Drug Administration (FDA) have been notified that the blister packs for products listed below are not compliant for consumer home use. As a result, we are voluntarily recalling and implementing corrective action for these selected blister packs.
This action is only necessary because the blister packs are not child-resistant. There are no quality or safety issues with the medicines for their intended use.
Patients should continue taking their medicine as directed by their physician, secure the affected blister packs so that they are out of the sight and reach of children, and contact Sandoz at 1-888-NOW NOVA (1-888-669-6682) for instructions. Products in bottles are NOT impacted by this recall.
To learn more about the Novartis products affected by this recall and requiring corrective action, please click hereto be re-directed to the Novartis website.
All blister pack configurations (listed below) that are identified as not child-resistant and potentially dispensed for in-home use require corrective action. To secure medicines in blister packs in the homes of consumers, Sandoz will provide child-resistant re-sealable pouches to store your medication. Consumers should immediately secure your blister packs out of the sight and reach of children, and contact us at 1-888-NOVA-NOW to request your pouch.
Here are some easy instructions on how to use your child-resistant, re-sealable pouch.
The products affected by the recall include production lots of the following medicines that have been distributed by Sandoz to date:
Azithromycin: 250mg tablets in 50 count unit dose blister packages.